Expression and significance of the novel tumor-suppressor gene SMG-1 in hepatocellular carcinoma

Oncology Reports

Volumn 31, Issue 6, 2014, Pages 2569-2578

  Han, Li Li ^a   Nan, Hao Cheng ^b   Tian, Tao ^a   Guo, Hui ^a   Hu, Ting Hua ^a   Wang, Wen Juan ^a   Ma, Jie Qun ^a   Jiang, Li Li ^a   Guo, Qian Qian ^a   Yang, Cheng Cheng ^a   Kang, Xiao Min ^a   Liu, Ying ^a   Gao, Yuan ^a   Liu, Qi Lun ^b   Nan, Ke Jun ^a  

^a XI'AN JIAOTONG UNIVERSITY   (China)

^b NINGXIA MEDICAL UNIVERSITY   (China)

Author keywords

Biomarker; Hepatocellular carcinoma; SMG 1

Indexed keywords

ALPHA FETOPROTEIN; BIOLOGICAL MARKER; PHOSPHATIDYLINOSITOL 3 KINASE; SMG1 PROTEIN, HUMAN; TUMOR SUPPRESSOR PROTEIN;

ADULT; AGED; ALPHA FETOPROTEIN BLOOD LEVEL; ARTICLE; CANCER CLASSIFICATION; CANCER GROWTH; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; CLINICAL FEATURE; CONTROLLED STUDY; DOWN REGULATION; EARLY CANCER; FEMALE; GENE EXPRESSION; GENE FUNCTION; HEPATITIS B; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SMG 1 GENE; TUMOR SUPPRESSOR GENE; TUMOR VOLUME; BIOSYNTHESIS; GENE EXPRESSION REGULATION; GENETICS; KAPLAN MEIER METHOD; LIVER TUMOR; MIDDLE AGED; PATHOLOGY; PROGNOSIS;

ADULT; AGED; CARCINOMA, HEPATOCELLULAR; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; KAPLAN-MEIER ESTIMATE; LIVER NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; PHOSPHATIDYLINOSITOL 3-KINASES; PROGNOSIS; TUMOR SUPPRESSOR PROTEINS;

EID: 84902168587     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2014.3125     Document Type: Article

References (34)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E and Forman D: Global cancer statistics. CA Cancer J Clin 61: 69-90, 2011.
2. He G and Karin M: NF-κB and STAT3 - key players in liver inflammation and cancer. Cell Res 21: 159-168, 2011.
3. Chen L, Ho DW, Lee NP, Sun S, Lam B, Wong KF, Yi X, Lau GK, Ng EW, Poon TC, Lai PB, Cai Z, Peng J, Leng X, Poon RT and Luk JM: Enhanced detection of early hepatocellular carcinoma by serum SELDI-TOF proteomic signature combined with alpha-fetoprotein marker. Ann Surg Oncol 17: 2518-2525, 2010.
4. Sidransky D: Emerging molecular markers of cancer. Nat Rev Cancer 3: 210-219, 2002.
5. El-Serag HB and Rudolph KL: Hepatocellular carcinoma: Epidemiology and molecular carcinogenesis. Gastroenterology 132: 2557-2576, 2007. (Pubitemid 46890874)
6. Zhao Y, Wang WJ, Guan S, Li HL, Xu RC, Wu JB, Liu JS, Li HP, Bai W, Yin ZX, Fan DM, Zhangand ZL and Han GH: Sorafenib combined with transurethral chemoembolization for the treatment of advanced hepatocellular carcinoma: a large-scale multicenter study of 222 patients. Ann Oncol 7: 1786-1792, 2013.
7. Denning G, Jamieson L, Maquat L, Thompson E and Fields A: Cloning of a novel phosphatidylinositol kinase-related kinase: characterization of the human SMG-1 RNA surveillance protein. J Biol Chem 276: 22709-22714, 2001.
8. Yamashita A, Ohnishi T, Kashima I, Taya Y and Ohno S: Human SMG-1, a novel phosphatidylinositol 3-kinase-related protein kinase, associates with components of the mRNA surveillance complex and is involved in the regulation of nonsense-mediated mRNA decay. Genes Dev 15: 2215-2228, 2001. (Pubitemid 32843834)
9. Grimson A, O'Connor S, Newman CL and Anderson P: SMG-1 is phosphatidylinositol kinase-related protein kinase required for nonsense-mediated mRNA decay in Caenorhabditis elegans. Mol Cell Biol 24: 7483-7490, 2004. (Pubitemid 39121476)
10. Gehen S, Staversky R, Bambara R, Keng P and O'Reilly M: SMG-1 and ATM sequentially and independently regulate the G1 checkpoint during oxidative stress. Oncogene 27: 4065-4074, 2008. (Pubitemid 351931993)
11. Cheung H, St Jean M, Beug S, Lejmi-Mrad R, LaCasse E, Baird S, Stojdl D,Screaton R and Korneluk R: SMG1 and NIK regulate apoptosis induced by Smac mimetic compounds. Cell Death Dis 2: e146, 2011.
12. Brumbaugh K, Otterness D, Geisen C, Oliveira V, Brognard J, Li X, Lejeune F, Tibbetts R, Maquat L and Abraham R: The mRNA surveillance protein hSMG-1 functions in genotoxic stress response pathways in mammalian cells. Mol Cell 14: 585-598, 2004. (Pubitemid 38739082)
13. Chen R, Yang Q, Chen Y, Oliveira V, Dalton W, Fearns C and Lee J: Kinome siRNA screen identifies SMG-1 as a negative regulator of hypoxia-inducible factor-1α in hypoxia. J Biol Chem 284: 16752-16758, 2009.
14. Masse I, Molin L, Mouchiroud L, Vanhems P, Palladino F, Billaud M and Solari F: A novel role for the SMG-1 kinase in lifespan and oxidative stress resistance in Caenorhabditis elegans. PLoS One 3: e3354, 2008.
15. González-Estévez C, Felix DA, Smith MD, Paps J, Morley SJ, James V, Sharp TV and Aboobaker AA: SMG-1 and mTORC1 act antagonistically to regulate response to injury and growth in planarians. PLoS Genet 3: e1002619, 2012.
16. Gubanova E, Issaeva N, Gokturk C, Djureinovic T and Helleday T: SMG-1 suppresses CDK2 and tumor growth by regulating both the p53 and Cdc25A signaling pathways. Cell Cycle 12: 3770-3780, 2013.
17. Roberts T, Ho U, Luff J, Lee C, Apte S, MacDonald K, Raggat L, Pettit A, Morrow C and Waters M: Smg1 haploinsufficiency predisposes to tumor formation and inflammation. Proc Natl Acad Sci USA 110: E285-E294, 2013.
18. Oliveira V, Romanow WJ, Geisen C, Otterness DM, Mercurio F, Wang HG, Dalton WS and Abraham RT: A protective role for the human SMG-1 kinase against tumor necrosis factor-α-induced apoptosis. J Biol Chem 283: 13174-13184, 2008.
19. Shiloh Y: ATM and related protein kinases: Safeguarding genome integrity. Nat Rev Cancer 3: 155-168, 2003.
20. Matter MS, Decaens T, Andersen JB and Thorgeirsson SS: Targeting the mTOR pathway in hepatocellular carcinoma: current state and future trends. J Hepatol 60: 855-865 2014.
21. Menon S, Yecies JL and Zhang HH: Chronic activation of mTOR complex 1 is sufficient to cause hepatocellular carcinoma in mice. Sci Signal 5: ra24, 2012.
22. Bassullu N, Turkmen I, Dayangac M, Yagiz Korkmaz P, Yasar R, Akyildiz M, Yaprak O, Tokat Y, Yuzer Y and Bulbul Dogusoy G: The predictive and prognostic significance of c-erb-B2, EGFR, PTEN, mTOR, PI3K, p27, and ERCC1 expression in hepatocellular carcinoma. Hepat Mon 12: e7492, 2012.
23. Villanueva A, Chiang DY, Newell P, Peix J, Thung S, Alsinet C, Tovar V, Roayaie S, Minguez B, Sole M, Battiston C, Van Laarhoven S, Fiel MI, Di Feo A, Hoshida Y, Yea S, Toffanin S, Ramos A, Martignetti JA, Mazzaferro V, Bruix J, Waxman S, Schwartz M, Meyerson M, Friedman SL and Llovet JM: Pivotal role of mTOR signaling in hepatocellular carcinoma. Gastroenterology 135: 1972-1983.e1-11, 2008.
24. Zhou L, Huang Y, Li J and Wang Z: The mTOR pathway is associated with the poor prognosis of human hepatocellular carcinoma. Med Oncol 27: 255-261, 2010.
25. Buitrago-Molina LE and Vogel A: mTor as a potential target for the prevention and treatment of hepatocellular carcinoma. Curr Cancer Drug Targets 9: 1045-1061, 2012.
26. Lee HE, Han N, Kim MA, Lee HS, Yang HK, Lee BL and Kim WH: DNA damage response-related proteins in gastric cancer: ATM, Chk2 and p53 expression and their prognostic value. Pathobiology 1: 25-35, 2014.
27. Valkov A, Kilvaer TK, Sorbye SW, Donnem T, Smeland E, Bremnes RM and Busund LT: The prognostic impact of Akt isoforms, PI3K and PTEN related to female steroid hormone receptors in soft tissue sarcomas. J Transl Med 9: 200, 2011.
28. Bhattacharya N, Mukherjee N, Singh RK, Sinha S, Alam N, Roy A, Roychoudhury S and Panda CK: Frequent alterations of MCPH1 and ATM are associated with primary breast carcinoma: clinical and prognostic implications. Ann Surg Oncol 3: 424-432, 2013.
29. Shin JU, Lee CH, Lee KT, Lee JK, Lee KH, Kim KM, Kim KM, Park SM and Rhee JC: Prognostic significance of ATM and cyclin B1 in pancreatic neuroendocrine tumor. Tumour Biol 5 1645-1651, 2012.
30. Xu W, Li JY, Wu YJ, Yu H, Shen QD, Li L, Fan L and Qiu HX: Prognostic significance of ATM and TP53 deletions in Chinese patients with chronic lymphocytic leukemia. Leuk Res 7: 1071-1077, 2008. (Pubitemid 351514787)
31. Llovet JM and Bruix J: Novel advancements in the management of hepatocellular carcinoma in 2008. J Hepatol 48 (Suppl 1): S20-S37, 2008.
32. Bruix J, Sherman M, Llovet JM, Beaugrand M and Lencioni R: Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol 35: 421-430, 2001. (Pubitemid 32844200)
33. Tseng PL, Tai MH, Huang CC, Wang CC, Lin JW, Hung CH, Chen CH, Wang JH, Lu SN, Lee CM, Changchien CS and Hu TH: Overexpression of VEGF is associated with positive p53 immunostaining in hepatocellular carcinoma (HCC) and adverse outcome of HCC patients. J Surg Oncol 5: 349-357, 2008.
34. Hsu H, Peng S, Lai P, Chu J and Lee P: Mutations of p53 gene in hepatocellular carcinoma correlate with tumor progression and patient prognosis: a study of 138 patients with unifocal HCC. Int J Oncol 6: 1341-1347, 1994. (Pubitemid 24180340)